Acadia Reports New Positive Data For Phase 2 Remlifanserin Study In Alzheimer's Psychosis
Acadia Pharmaceuticals (ACAD) reported positive Phase 2 trial results for Remlifanserin in treating Alzheimer's disease psychosis. The 60 mg dose showed improvement over placebo in key measures. ACAD stock closed at $18.32, down 1.87%.
How this was made

The 30-second read
Why it matters
The trial results provide the first substantive efficacy readout for remlifanserin, a 5HT2A inverse agonist targeting Alzheimer's psychosis.
Market read
First‑report Phase 2 data for a neuro‑psychiatric drug; could influence ACAD stock and related biotech peers.
What to watch
Potential safety signals or regulatory hurdles could temper enthusiasm despite the efficacy signals.
Background
Acadia presented the data at the 2026 Clinical Trials on Alzheimer's Disease conference in Boston.
Ticker impact
Acadia Pharmaceuticals released new Phase 2 RADIANT trial data for remlifanserin showing statistically significant improvement on secondary endpoints.
potential upside as investors price in the encouraging trial results
Phase 2 data is a material catalyst for a biotech; the 60 mg dose showed improvement over placebo on CGI‑S‑ADP and NPI scores, which often precedes a share price bounce.
Market effects
May boost confidence in the Alzheimer's psychosis therapeutic space and could lift peer biotech stocks developing similar agents.
Limited to U.S. biotech sector; no broader regional effect.
Relevant to global investors tracking neuro‑psychiatric drug pipelines.
Counterpoint
The data, while positive, still reflects a Phase 2 study; investors may wait for Phase 3 confirmation before committing.
Key entities
- companyAcadia Pharmaceuticals Inc.
Developer of remlifanserin, listed on NASDAQ.

